Serum uric acid as an independent predictor of early death after acute stroke

Circulation Journal

Volumn 71, Issue 7, 2007, Pages 1120-1127

  Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b,c   Tziomalos, Konstantinos ^a   Sileli, Maria ^a   Savvatianos, Savvas ^a   Kakafika, Anna ^a,b   Gossios, Thomas ^a   Krikis, Napoleon ^a   Moschou, Irene ^a   Xochellis, Michael ^a   Athyros, Vassilios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Intracerebral hemorrhage; Ischemic stroke; Prognosis; Uric acid

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UREA; URIC ACID;

AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE REGRESSION; PREDICTION; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SMOKING; STROKE; UNIVARIATE ANALYSIS; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; LENGTH OF STAY; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS; URIC ACID;

EID: 34347230840     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1120     Document Type: Article

References (90)

1. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421-1431.
2. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996; 27: 63-68.
3. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort: World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999; 10: 391-397.
4. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med 2004; 164: 1546-1551.
5. Kawamoto R, Tomita H, Oka Y, Kodama A, Ohtsuka N, Kamitani A. Association between uric acid and carotid atherosclerosis in elderly persons. Intern Med 2005; 44: 787-793.
6. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam study. Stroke 2006; 37: 1503-1507.
7. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992: National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410.
8. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, de Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
9. Mazza A, Pessina AC, Pavei A, Scarpa R, Tikhonoff V, Casiglia E. Predictors of stroke mortality in elderly people from the general population: The CArdiovascular STudy in the ELderly. Eur J Epidemiol 2001; 17: 1097-1104.
10. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. Hypertension 2000; 36: 1072-1078.
11. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: A marker of chronic inflammation. Eur Heart J 1998; 19: 1814-1822.
12. Sakai H, Tsutamoto T, Tsutsui T, Tanaka T, Ishikawa C, Horie M. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J 2006; 70: 1006-1011.
13. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-639.
14. Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metab Res Rev 2006; 22: 79-82.
15. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
16. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-139.
17. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-650.
18. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-954.
19. Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905-915.
20. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. Guidelines for the early management of patients with ischemic stroke: A Scientific Statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056-1083.
21. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 Guidelines update: A Scientific Statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-923.
22. Milionis HJ, Kalantzi KJ, Goudevenos JA, Seferiadis K, Mikhailidis DP, Elisaf MS. Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med 2005; 258: 435-441.
23. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis D. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66: 1714-1715.
24. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-1956.
25. Cherubini A, Polidori MC, Bregnocchi M, Pezzuto S, Cecchetti R, Ingegni T, et al. Antioxidant profile and early outcome in stroke patients. Stroke 2000; 31: 2295-2300.
26. Wong KY, MacWalter RS, Fraser HW, Crombie I, Ogston SA, Struthers AD. Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 2002; 23: 788-793.
27. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
28. Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia pacific region: A pooled analysis. Hypertension 2003; 42: 69-75.
29. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric aid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension 2005; 45: 28-33.
30. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474-480.
31. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-464.
32. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-821.
33. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
34. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360.
35. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897.
36. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293.
37. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-281.
38. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999; 9: 119-131.
39. Sun AY, Chen YM. Oxidative stress and neurodegenerative disorders. J Biomed Sci 1998; 5: 401-414.
40. Maxwell SR, Lip GY. Free radicals and antioxidants in cardiovascular disease. Br J Clin Pharmacol 1997; 44: 307-317.
41. Gariballa SE, Hutchin TP, Sinclair AJ. Antioxidant capacity after acute ischaemic stroke. Q J Med 2002; 95: 685-690.
42. Spranger M, Krempien S, Schwab S, Donneberg S, Hacke W. Superoxide dismutase activity in serum of patients with acute cerebral ischemic injury: Correlation with clinical course and infarct size. Stroke 1997; 28: 2425-2428.
43. Leinonen JS, Ahonen JP, Lonnrot K, Jehkonen M, Dastidar P, Molnar G, et al. Low plasma antioxidant activity is associated with high lesion volume and neurological impairment in stroke. Stroke 2000; 31: 33-39.
44. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376: 333-337.
45. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002; 33: 1048-1052.
46. Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 1999; 446: 305-308.
47. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricaemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 2000; 49: 511P.
48. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid. Biochem J 1999; 340: 143-152.
49. Boogaerts MA, Hammerschmidt DE, Roelant C, Verwilghen RL, Jacob HS. Mechanisms of vascular damage in gout and oxalosis: Crystal induced, granulocyte mediated, endothelial injury. Thromb Haemost 1983; 50: 576-580.
50. Duff GW, Atkins E, Malawista SE. The fever of gout: Urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes. Trans Assoc Am Physicians 1983; 96: 234-245.
51. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: The Minoh Study. Circ J 2005; 69: 386-391.
52. Kondo N, Nomura M, Nakaya Y, Ito S, Ohguro T. Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. Circ J 2005; 69: 452-457.
53. Patetsios P, Rodino W, Wisselink W, Bryan D, Kirwin JD, Panetta TF. Identification of uric acid in aortic aneurysms and atherosclerotic artery. Ann NY Acad Sci 1996; 800: 243-245.
54. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: An active component or an innocent bystander? Metabolism 2006; 55: 1293-1301.
55. Ishizaka N, Ishizaka Y, Toda EI, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25: 1038-1044.
56. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: The CARDIA study [Coronary Artery Risk Development in Young Adults]. Ann Epidemiol 1998; 8: 250-261.
57. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans: The Atherosclerosis Risk in Communities baseline study. Diabetes Care 1996; 19: 414-418.
58. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933.
59. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-127.
60. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid: A facet of hyperinsulinaemia. Diabetologia 1987; 30: 713-718.
61. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290: 625-631.
62. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006; 19: 1055-1062.
63. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
64. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005; 21: 1157-1159.
65. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005; 36: 1372-1376.
66. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssönen K, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37: 806-811.
67. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke 2006; 37: 1060-1064.
68. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: A prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005; 36: 1366-1371.
69. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
70. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, et al; Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563-572.
71. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002; 33: 1863-1868.
72. Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statins in stroke prevention and carotid atherosclerosis: Systematic review and metaanalysis. Stroke 2004; 35: 2902-2909.
73. Zuliani G, Cherubini A, Atti AR, Ble A, Vavalle C, Di Todaro F, et al. Low cholesterol levels are associated with short-term mortality in older patients with ischemic stroke. J Gerontol A Biol Sci Med Sci 2004; 59: 293-297.
74. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J. Better outcome after stroke with higher serum cholesterol levels. Neurology 2000; 54: 1944-1949.
75. Dyker AG, Weir CJ, Lees KR. Influence of cholesterol on survival after stroke: Retrospective study. BMJ 1997; 314: 1584-1588.
76. Onder G, Landi F, Volpato S, Fellin R, Carbonin P, Gambassi G, et al. Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med 2003; 115: 265-271.
77. Brescianini S, Maggi S, Farchi G, Mariotti S, Di Carlo A, Baldereschi M, et al, for the ILSA Group. Low total cholesterol and increased risk of dying: Are low levels clinical warning signs in the elderly?: Results from the Italian Longitudinal Study on Aging. J Am Geriatr Soc 2003; 51: 991-996.
78. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001; 358: 351-355.
79. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and mortality: Which is the cause and which is the effect? Circulation 1995; 92: 2396-2403.
80. Abbott RD, Sharp DS, Burchfiel CM, Curb JD, Rodriguez BL, Hakim AA, et al. Cross-sectional and longitudinal changes in total and high-density- lipoprotein cholesterol levels over a 20-year period in elderly men: The Honolulu Heart Program. Ann Epidemiol 1997; 7: 417-424.
81. Manolio TA, Ettinger WH, Tracy RP, Kuller LH, Borhani NO, Lynch JC, et al. Epidemiology of low cholesterol levels in older adults. Circulation 1993; 87: 728-737.
82. Iribarren C, Jacobs DR Jr, Sidney S, Claxton AJ, Feingold KR. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 1998; 121: 335-347.
83. Woo J, Lam CWK, Wong HY, Teoh R, Nicholls MG. Acute and long-term changes in serum lipids after acute stroke. Stroke 1990; 21: 1407-1411.
84. Lindgren A, Nilsson-Ehle P, Norrving B, Johansson BB. Plasma lipids and lipoproteins in subtypes of stroke. Acta Neurol Scand 1992; 86: 572-578.
85. Patel A, Woodward M, Campbell DJ, Sullivan DR, Colman S, Chalmers J, et al. Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J 2005; 26: 1910-1915.
86. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Collaborative Study Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767.
87. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
88. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161-4175.
89. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-599.
90. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734.